AquaBounty Technologies, Inc. (NASDAQ:AQB) Short Interest Update

AquaBounty Technologies, Inc. (NASDAQ:AQB) was the target of a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 66,398 shares, a growth of 90.3% from the February 26th total of 34,899 shares. Approximately 1.8% of the shares of the company are short sold. Based on an average trading volume of 27,836 shares, the days-to-cover ratio is presently 2.4 days.

Institutional Trading of AquaBounty Technologies

An institutional investor recently bought a new position in AquaBounty Technologies stock. Two Sigma Investments LP acquired a new position in AquaBounty Technologies, Inc. (NASDAQ:AQB) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 37,565 shares of the company’s stock, valued at approximately $84,000. Two Sigma Investments LP owned 0.97% of AquaBounty Technologies at the end of the most recent quarter. Hedge funds and other institutional investors own 8.92% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AquaBounty Technologies in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

AquaBounty Technologies Price Performance

Shares of AQB traded down $0.03 during mid-day trading on Friday, hitting $0.91. The stock had a trading volume of 2,958 shares, compared to its average volume of 34,326. AquaBounty Technologies has a 52 week low of $0.60 and a 52 week high of $2.95. The business has a fifty day moving average price of $0.93 and a 200-day moving average price of $1.14. The firm has a market cap of $3.53 million, a P/E ratio of -1.10 and a beta of 1.29.

AquaBounty Technologies Company Profile

AquaBounty Technologies, Inc is a biotechnology company focused on aquaculture innovation through the development and commercialization of genetically engineered fish. Its flagship product, AquAdvantage Salmon, is an Atlantic salmon strain enhanced with a growth hormone gene that enables faster growth and more efficient feed conversion compared with conventional farmed salmon. By integrating biotechnology into seafood production, AquaBounty aims to address global protein demand while reducing the environmental footprint associated with marine aquaculture.

Founded in 1991, AquaBounty is headquartered in Maynard, Massachusetts, and operates a state-of-the-art, land-based incubation and grow-out facility in Panama.